AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A solid dispersion composition comprising cefditoren pivoxil and ~~at least 0.1 mg, preferably at least 5 mg,~~ 0.1 to 200 mg of a ~~sugar~~ sucrose ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

2. **(Currently amended)** The solid dispersion composition according to claim 1, comprising ~~0.1 mg to 200 mg, preferably at least~~ 5 to 100 mg~~, more preferably 5 to 50 mg,~~ of the ~~sugar~~ sucrose ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

3. **(Previously presented)** The solid dispersion composition according to claim 1, which further comprises a pharmaceutically acceptable water-soluble polymer.

4. **(Currently amended)** The solid dispersion composition according to claim 3, which contains ~~at least 1 mg, preferably~~ 1 to 100 mg~~, more preferably 1 to 50 mg,~~ of the water-soluble polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

5. **(Currently amended)** The solid dispersion composition according to claim 1, which contains ~~0.1 to 200 mg of the sugar ester fatty acid and~~ 1 to 100 mg of the water-soluble polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

6. **(Currently amended)** The solid dispersion composition according to claim 1, which contains 5 to 100 mg of the ~~sugar~~ sucrose ester fatty acid and 1 to 50 mg of ~~the~~ a pharmaceutically acceptable water-soluble polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

7. (Previously presented) The solid dispersion composition according to claim 3, wherein the pharmaceutically acceptable water-soluble polymer is one or more water-soluble polymers selected from the group consisting of hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

8. (Currently amended) The solid dispersion composition according to claim 1, wherein ~~the~~ an amorphousness-maintaining period of cefditoren pivoxil is at least 3 days when suspended in water at a cefditoren pivoxil concentration of 10 mg/ml.

9. (Previously presented) An antibiotic pharmaceutical preparation comprising the composition of claim 1 together with a pharmaceutically acceptable additive.

10. (Currently amended) A liquid composition comprising cefditoren pivoxil and 0.1 to 200 mg ~~at least 0.1 mg, preferably at least 5 mg,~~ of ~~the~~ a ~~sugar~~ sucrose ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil, which is obtainable by dissolving or suspending ~~a~~ the solid dispersion composition of claim 1 in a medium.

11. (Currently amended) A liquid composition comprising cefditoren pivoxil and 0.1 to 200 mg ~~at least 0.1 mg, preferably at least 5 mg,~~ of ~~the~~ a ~~sugar~~ sucrose ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil, which is obtainable by dissolving or suspending ~~a~~ the pharmaceutical preparation of claim 9 in a medium.